EBCC-12 Scientific programme

Wednesday 18 March 2020

Opening Ceremony: Opening of the 12th European Breast Cancer Conference
10:00 - 11:00  Picasso

10:00 Welcome
Chair: Nadia Harbeck (Germany)

10:05 Introduction of the European Breast Cancer Arts and Humanities Award
Co-Chair: Tanja Spanic (Slovenia)

10:10 Arts and Humanities Award - Daily Living Although-Animation
Awardee: Sari Neyman (Finland)

10:20 Introduction of the European Breast Cancer Science Award - Emmanuel van der Schueren Lecture
Chair: Nadia Harbeck (Germany)

10:25 Research and education in oncology: Two sides of the same coin
Awardee: Fátima Cardoso (Portugal)

Clinical Science Symposium: The Axilla: How to Reduce Overtreatment
11:15 - 12:45  Picasso

11:15 Radiation oncology
Speaker: Elzbieta Senkus-Konefka (Poland)

11:30 Imaging
Speaker: Ruud Pijnappel (Netherlands)

11:45 Surgeon in the context of pre-operative systemic therapy
Speaker: Isabel T. Rubio (Spain)
1. Understand surgical management of the axilla after neoadjuvant treatment
2. Discuss techniques to accurately assess the axilla after neoadjuvant treatments
3. Update de-escalation in surgical treatments in the axilla.

12:00 Surgeon in the context of upfront surgery
Speaker: V. Galimberti (Italy)

12:15 Omitting completion axillary lymph node dissection in sentinel lymph node-positive breast cancer: first results from the swedish prospective SENOMIC trial and an external validity analysis of the ongoing SENOMAC trial
Oral Abstract SP: Jana De Boniface (Sweden)
The generalisability of randomised clinical trials: An interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer 1A
Jana De Boniface (Sweden)

Omitting completion axillary lymph node dissection after sentinel node micrometastases in breast cancer - first results from the Swedish prospective SENOMIC trial 1B
Yvette Andersson (Sweden)
12:30  Tailored axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer patients is safe: 3-year follow-up of the MARI protocol
Oral Abstract SP: Marie Jeanne Vrancken - Peeters (Netherlands)

Clinical Science Symposium: Metastatic Breast Cancer
11:15 - 12:45  Dali

Chair: Fátima Cardoso (Portugal)
Chair: Karen Benn (Italy)
11:15  Local regional treatment of metastases
Speaker: Jens Ricke (Germany)
11:30  Management of triple -ve
Speaker: Giuseppe Curigliano (Italy)
11:45  Management of HER2 +ve
Speaker: Nadia Harbeck (Germany)
12:00  Management of luminal breast cancer
Speaker: Alessandra Gennari (Italy)
12:15  Panel-guided personalized medicine in metastatic breast and gynecological cancer: First experiences at the Comprehensive Cancer Centre Munich and clinical relevant changes over time
Oral Abstract SP: Rachel Wuerstlein (Germany)
12:30  Contemporary picture of metastatic breast cancer: characteristics and outcomes of 22000 women from the ESME cohort 2008-2016
Oral Abstract SP: Elise Deluche (France)

Clinical Science Symposium: Latest Practices in Follow up of Patients
11:15 - 12:45  Goya

Chair: Elizabeth Bergsten-Nordstrom (Sweden)
Chair: Inez Vaz Duarte Luis. (France)
11:15  Reasons and standards for follow up
Speaker: Inez Vaz Duarte Luis. (France)
11:30  Apps and adherence: Overview
Speaker: Timo Schinköthe (Germany)
11:45  Lifestyle/Exercise - for preventing recurrence and improving QOL
Speaker: Melinda Irwin (USA)
12:00  Complementary medicine
Speaker: Caroline Hoffman (United Kingdom)
1. To identify complementary medical approaches proven to support people with breast cancer
2. To discuss research for the benefit of complementary medicine in supporting symptoms and side effects of breast cancer and its treatments
3. To discuss research evidence for complementary medicine in supporting living well with breast cancer
12:15  Patient perspective - how individual patients manage follow up
Speaker: Barbara Klein (Italy)
Oral Abstract SP: Iris Kramer (Netherlands)

Young Investigators Session: Round Table Discussions
13:30 - 14:30  Room 129-130

Introduction to the session
To be announced ()
Young investigators can discuss difficult cases or struggles from clinics on how to treat their patients with a senior or young expert

Table 1
Local treatment
Moderator: Isabel T. Rubio (Spain)

Local treatment
Moderator: Icro Meattini (Italy)

Table 2
Elderly patients
Moderator: Etienne Brain (France)

Table 3
Young Patients (+ fertility)
Moderator: Matteo Lambertini (Italy)

Table 4
De-escalation and escalation of systemic therapy
Moderator: Fátima Cardoso (Portugal)

Table 5
Oligometastatic disease
Moderator: Jens Ricke (Germany)

Poster in the Spotlight: Poster in the Spotlight I
13:30 - 14:00  Poster Area/Exhibition Hall

Moderator: David A. Cameron (United Kingdom)

PB-001 Salivary metabolomics with artificial intelligence-based methods for breast cancer detection and subtype prediction
Moderated discussion

PB-002 Sense of coherence as predictor of quality of life in early breast cancer patients
L. Hakamies-Blomqvist, N. Vähäräaho, C. Blomqvist, P.L. Kellokumpu-Lehtinen, R. Huovinen, T. Saarto, C. Hakulinen (Finland)
Moderated discussion

PB-003 Does mesh improve patient satisfaction and health-related quality of life after implant-based breast reconstruction? A multicentre prospective cohort study
E. Sewart, N. Turner, E. Conroy, R. Cutress, J. Skillman, L. Whisker, S. Thrush, N. Barnes, C. Holcombe, S. Potter (United Kingdom)
Moderated discussion
Plenary Session: Keynote Lecture, Best and Late Breaking Abstract Presentations
14:45 - 16:15  Picasso

Chair: Nadia Harbeck (Germany)
Chair: Emiel J. T. Rutgers (Netherlands)

14:45  PROMs, PREMs: Problems and Solutions  
Keynote Speaker: Amylou Dueck (USA)

15:15  Clinical Utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial  
Oral Abstract SP: Otto Metzger (USA)

15:30  The risk of cardiovascular disease in irradiated breast cancer patients: the role of cardiac calcifications and adjuvant treatment  
Oral Abstract SP: Helena Verkooijen (Netherlands)

15:45  Bridging the age gap: improved decision making for older women with early breast cancer, a cohort and cluster randomised analysis  
Oral Abstract SP: Lynda Wyld (United Kingdom)
  Impacts of omission of breast cancer surgery in older women with ER+ early breast cancer. A risk stratified analysis of survival and quality of life outcomes  
Lynda Wyld (United Kingdom)
  Cluster randomised trial to evaluate the clinical benefits of decision support interventions for older women with operable breast cancer.  
Lynda Wyld (United Kingdom)

16:00  to be announced

Debate: This House Believes That no Patient, with Luminal A like Node Positive Early Breast Cancer, Needs Chemotherapy
16:30 - 17:30  Picasso

Moderator: Etienne Brain (France)
16:30  Speaker in favour: Christos Sotiriou (Belgium)
16:45  Speaker against: Wolfgang Janni (Germany)
17:00  Seconder in favour: Sabine Linn (Netherlands)
17:10  Seconder against: Patrick Neven (Belgium)
17:20  Voting/Conclusion

Best Practice Session: End of Life Care
16:30 - 17:30  Miro

Chair: Sema Erdem (Turkey)
16:30  Palliative care specialist: prognostication  
Expert: Rachel Wuerstein (Germany)
16:40  Medical Oncologist  
Expert: Suzette Delaloge (France)
16:50  **Patient and family**  
   Expert: Eva Masel (Austria)  
   Nurse (Panel Member)  
   Expert: Deborah Fenlon (United Kingdom)

17:00  **Panel discussion**

**Society Session: European Society of Pathology (ESP) - Breast Cancer TNM 8 - The Pathologists’ Perspective**

16:30 - 18:00  
Chair: Zsuzsanna Varga (Switzerland)  
Chair: Tibor Tot (Sweden)  
**Introduction**

16:30  **The importance of reproducible staging of breast cancer**  
Speaker: Zsuzsanna Varga (Switzerland)  

16:50  **Stage migration in case of genetic testing**  
Speaker: Gabor Cserni (Hungary)  

17:10  **LCIS: benign or malignant**  
Speaker: Maria Pia Foschini (Italy)  

17:30  **The problems**  
Speaker: Tibor Tot (Sweden)  

17:50  **Discussion**

**Young Investigators Session: Scientific Small Group Discussions**

16:30 - 18:00  
Room 129-130  
**Introduction to the session**  
To be announced ()  
The small group discussion will focus on research proposals/trial ideas that young investigators may have. Each small group will be under the supervision of a senior or young expert that can also help frame the ideas and suggest finished trials from which data could be effectively used to explore new research questions.

**Table 1**  
**Biomarkers**  
Moderator: Michail Ignatiadis (Belgium)

**Table 2**  
**Gene expression signatures/prognostic factors; further exploring the mindact database**  
Moderator: Emiel J. T. Rutgers (Netherlands)

**Table 3**  
**Male breast cancer**  
Moderator: Fátima Cardoso (Portugal)

**Table 4**  
**Using cancer registry data for research**  
Moderator: Jonas Bergh (Sweden)

**Table 5**
### Poster Session: Follow up

#### PB-008 Metachronous breast cancer: An observational study in a single institution
W.P. Lee, S.S. Shetty, C.M.J. Seah, J.W.C. Kam, S.M. Tan (Singapore)

#### PB-009 Improvement of recurrent rates and survival in patients with primary breast cancer according to subtypes
M. Nakano, R. Nishimura, T. Osako, Y. Okumura, M. Fujisue, N. Arima (Japan)

#### PB-010 Characteristics of ipsilateral breast tumor recurrence after breast conserving surgery: Single center experience
H. Lee, M. Lee, J. Cho, S. Kang (South Korea)

#### PB-011 Do patients with breast cancer receive the optimal personalized follow up?
J. Van Hoeve, J. Ankersmid, L. Strobbe, M. Sprengers, J. Verloop, R. Schrijer, B. Kistemaker, S. Siesling (Netherlands)

#### PB-012 Long-term prognosis correlates with residual disease in breast and axillary nodes but not with initial nodal status: Follow-up data from the Swedish prospective multicenter trial evaluating sentinel lymph node biopsy in the neoadjuvant setting
L. Zetterlund, F. Celebioglu, J. Frisell, J. De Boniface (Sweden)

#### PB-013 Development of an information standard for breast cancer in the Netherlands

#### PB-014 PD-L1 and HSP-70 molecules are part of immunosuppressive environment in the deep layer of the lymphocyte predominant breast cancer (LPBC)

#### PB-016 Prognosis according to the timing of recurrence in breast cancer
S. Jung, S.Y. Bae, H.W. Yang, J.W. Bae (South Korea)

### Poster Session: Local Regional Treatment - Surgery

#### PB-017 Vacuum intraoperative specimen mammography: A novel technique
M.G. Bai, A. Surace, G. Gregori, C. De Sanctis, V. Marra, C. Marengo, D. Tota, F. Borrella, C. Benedetto, M.P. Mano (Italy)

#### PB-018 Angiosome theory findings using new protocol of CT-angiography improves outcomes in DIEP-flap reconstruction surgery in breast cancer patients

#### PB-019 The value of removing more than one sentinel node in breast cancer
J. Lopes Cardozo, J. Vanhommerig, S. Donkervoort (Belgium)

#### PB-020 Long term survival outcomes of “LORIS-low risk” ductal carcinoma in-situ from a territory-wide cancer registry in Hong Kong
M. Co, A. Kwong (Hong Kong)

#### PB-021 Predictors of surgical margin involvement in breast cancer surgery
A. Goikoetxea Urdaíñ, I. Equiras Córdoba, I. Otegi Altolaguirre, N. Moras Perez, M.A. Sanz de Pablo, C. Artieda Soto, P. Armendáriz Rubio (Spain)
PB-022 Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for small breast carcinomas

PB-023 Non-intervention vs. surgical interventions in (Low-Risk) Ductal Carcinoma In Situ: A DCIS multi-state model for decision analytics
D. Byng, V. Retèl, M. Schapaeveld, J. Wesseling, W. Van Harten (Netherlands)

PB-024 Psycho-social assessment of post-surgery outcomes after breast reconstruction surgery
L. Busheri (India)

PB-025 Combined iodinated radiographic contrast and Tc99 radioisotope (i-ROLL) as technical improvement for the preoperative localization of non-palpable breast lesions: A comparative study with ROLL
M. Medarde Ferrer, J. Del Riego Ferrari, O. Aparicio Rodriguez, J.C. Martin Miramón, V. Lucas Guerrero, Á. Martin Oloriz, S. Navarro Soto (Spain)

PB-026 Quality of life improvement and pain reduction in implant-based breast reconstruction by means of selective pectoralis major muscle denervation
M. Bernini, I. Meattini, S. Sordi, L. Orzalesi, J. Nori Cucchiari, V. Scotti, I. Desideri, S. Bianchi, L. Livi (Italy)

PB-027 Good cosmetic outcome after vacuum assisted excision of benign breast lesions
E. Van De Voort, T. Klem, G. Struijk, E. Birnie, R. Sinke, A. Ghandi (Netherlands)

PB-028 Breast Lesion Excision System as a treatment method for small invasive breast cancers
W. Sanderink, L. Strobbe, P. Bult, W. Vreuls, I. Sechopoulos, N. Karssemeijer, R. Mann (Netherlands)

PB-029 Accurate axillary staging by superparamagnetic iron oxide-enhanced MR imaging as an alternative to sentinel node biopsy in breast cancer
K. Motomura, S. Hashidume, Y. Tabuchi, M. Kouda, S. Kawamoto (Japan)

PB-030 SPIO-guided Sentinel Lymph Node Biopsy (SLNB) in early Breast Cancer – first monoinstitutional data and perspectives
S. Paepke, M. Kiechle, M. Karsten, J.U. Blohmer, G. Schmidt, J. Stassek, T. Kühn, M. Thill (Germany)

PB-031 Association of axillary lymph node evaluation with survival in women aged 70 years or older with breast cancer
S. Luo, J. Zhang, C. Song (China)

PB-032 Mesh-Pocket supported prepectoral implant-based breast reconstruction: Final results of a retrospective analysis
S. Paepke, M. Kiechle, C. Ankel, R. Ohlinger, M. Thill, K. Kelling, K. Baumann, T. Pursche, H.J. Strittmatter, A. Faridi (Germany)

PB-033 How I do it: Lymphatic mapping and sentinel lymph node biopsy with Indocianine Green in Breast Cancer patients, a prospective trial experience

PB-034 Oncological safety of oncoplastic breast conserving surgery- compare with conventional surgery
Y. Kim, W. Han (South Korea)

PB-035 Oncoplastic breast-conserving surgery offers low local recurrence rates and excellent survival rates despite worse tumor characteristics
C. André, C. Holsti, A. Svenner, I. Oikonomou, H. Ikonomidis Sackey, M. Appelgren, A. Johansson, J. De Boniface (Sweden)

PB-036 Omission of axillary dissection after neoadjuvant chemotherapy for node-positive primary breast cancer
A. Matsumoto, U. Yasuko, D. Tsukahara, H. Jinno (Japan)

PB-037 Neoadjuvant chemotherapy is not a contraindication for nipple-sparing mastectomy: definitive results
PB-038 Variation in the rates of surgical treatment of older women with operable breast cancer between UK breast units: analysis of the Bridging the Age Gap Study
J. Morgan, G. Holmes, C. Martin, S. Walters, K.L. Cheung, R. Audisio, M. Reed, L. Wyld (United Kingdom)

PB-039 Quality of life outcomes following breast surgery in older women with operable breast cancer: analysis of the Bridging the Age Gap study
J. Morgan, G. Holmes, C. Martin, S. Walters, K.L. Cheung, R. Audisio, M. Reed, L. Wyld (United Kingdom)

PB-040 Patient Reported Outcome and cosmetic evaluation following implant-based breast-reconstruction with a titanized polypropylene mesh: a prospective clinical study in 269 patients

PB-041 Evaluation of the breast lesion excision system, a percutaneous,vacuum assisted,intact- specimen, breast biopsy device
G. Kinoglou, V. Antoniou, C. Kalyvopoulos, N. Vrenzos (Greece)

PB-042 Hospital variation in the use of Sentinel Lymph Node Biopsy for patients with a biopsy diagnosis of ductal carcinoma in situ
C. Meurs, M. Menke-Pluijmers, S. Sabine, P. Westenend (Netherlands)

PB-043 Radioactive seed versus wire-guided localization for ductal carcinoma in situ of the breast: comparable resection margins
M.C. Agahozo, S.A.M. Berghuis, E. Van den Broek, L.B. Koppert, I.M. Obdeijn, C.H.M. Van Deurzen (Netherlands)

PB-044 Predicting lymph node metastases for biopsy diagnosis ductal carcinoma in situ: the DCIS-met model
C. Meurs, J. Van Rosmalen, M. Menke-Pluijmers, S. Siesling, P. Westenend (Netherlands)

PB-045 Optimization of wire-guided technique with bracketing reduces resection volumes in breast-conserving surgery for early breast cancer
Y. Civil, K. Duvivier, P. Perin, A. Baan, S. Van der Velde (Netherlands)

PB-046 Endoscopic nipple-areolar complex sparing mastectomy : a single institution’s early experience
H.Y. Lee, C. Young Woo, Y. Da Young, S. Gil Soo (South Korea)

PB-047 A Randomised Controlled Trial (RCT) of 3-dimensional simulation of the aesthetic outcome of Breast Conserving Treatment (BCT)
A. Godden, A. Micha, C. Pitches, L. Wolf, K. Krupa, P. Barry, J. Rusby (United Kingdom)

PB-048 Predicting postoperative complications in older patients with breast cancer

PB-049 Breast cancer in elderly patients: are we choosing wisely? A critical review of the breast unit of Trieste

PB-050 Cosmetic outcome and symmetry for patients who have undergone bilateral therapeutic mammoplasty for breast cancer
K. Gulis, P.O. Bendahli, T. Svensjö, L. Rydén (Sweden)

PB-051 A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer
M. Beek, P. Gobardhan, E. Klompenhouwer, M. Menke-Pluijmer, P. Steenvoorde, J. Merkus, H. Rutten, A. Voogd, E. Luiten (Netherlands)

PB-052 Sentinel node biopsy before and after the introduction of sentimag at a tertiary academic breast unit
F. Malherbe, L. Roodt, F. Noor, K. Chibuye, L. Cairncross (South Africa)

PB-053 Which are the predictive factors for the status of resection margins in breast conserving surgery and how they influence the overall survival and local recurrence?

PB-054 Knowledge attitude and practice of surgeons for breast conserving surgery: results from an Indian cohort
PB-055 Current clinical practice and determinants of the use of delayed breast reconstruction in the Netherlands
P. Van Egdom, K. De Ligt, MSc, L. De Munck, H. Rakhorst, M. Mureau, L. Koppert, S. Siesling (Netherlands)

PB-056 Clinical, imaging and pathology factors related to residual axillary disease after neoadjuvant treatment

PB-057 The impact of radiotherapy on patient-reported outcomes of immediate implant-based breast reconstruction: Results of a prospective multicentre cohort study
E. Sewart, N. Turner, E. Conroy, R. Cutress, J. Skillman, L. Whisker, S. Thrush, N. Barnes, C. Holcombe, S. Potter (United Kingdom)

PB-058 P53 and axillary tumor burden in breast cancer

PB-062 Women diagnosed with Ductal Carcinoma In Situ (DCIS) and healthcare providers’ views on active surveillance for DCIS. Results from focus groups and in-depth interviews

PB-063 Breast conserving surgery in breast cancer after neoadjuvant chemotherapy – opportunity of radioopaque tumor marking clips
G. Iancu, L. Mustata, L. Tuinea, A. Corha, B. Median, G. Peltecu, D. Median (Romania)

PB-066 Versatility, clinical outcomes and mammographic follow-up of Chest Wall Perforator Flaps (CWPF): a single-centre experience

PB-067 Comparative accuracy of preoperative tumour size of invasive ductal carcinoma on Magnetic Resonance Imaging, Digital Breast Tomosynthesis, Ultrasound and Computed Tomography: Radiologic-pathologic incongruence and clinical implications
Retrospective analysis of survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis
S. Xianfu, W. Yingjie, H. Tao (China)

Internal audit of an Indian breast oncosurgery unit using EUSOMA guidelines
S. Gupta, N. Gupta, G. Kadayaprapth (India)

Selective axillary dissection after axillary reverse mapping in node positive breast cancer patients to prevent breast cancer related lymphedema. The issue of safety.
M. Gennaro, S. Segattini, C. Listorti, I. Maugeri, V. Capizzi, M. Maccaro, S. Folli (Italy)

Predictors of seroma formation after breast cancer surgery
H. Vos, M. Reymen, L. Vandezande, T. Karman, A. Van Vugt, S. Vanderheyden, I. Nevelsteen, A. Smeets (Belgium)

Nationwide population-based study: patterns of care in young breast cancer patients in the Netherlands
N. Maliko, N. Bijker, M. Bos, M.J. Vrancken Peeters (Netherlands)

Defining a ‘dedicated’ breast cancer team
N. Maliko, N. Bijker, M. Wouters, M.J. Vrancken Peeters (Netherlands)

Predictive factors involved in determining response to neoadjuvant chemotherapy in breast cancer and impact of response on 5 years disease free survival and overall survival
B. Rehman, M.A. Parvaiz (Pakistan)

Male breast cancer: A high volume centre experience
F. Combi, S. Papi, E. Palma, A. Gambini, A. Andreotti, G. Esposito, G. Tazzoli (Italy)

Surgical margin involvement increases distant recurrence, not just local recurrence
S. Michael, S. Bowers, J. Ooi, M. Absar, S. Ellenbogen, N. Bundred (United Kingdom)

Size discrepancy of residual tumor between post chemotherapy sonography and on post excision histopathology after Neoadjuvant chemotherapy and its impact on 5 years disease free survival
M.A. Parvaiz, N. Khanum, B. Rehman, M.Z. Chuadhary, N. Javed, A.I. Khan, S. Afzal, R. Naheed, J. Mohsin (Pakistan)

Trends of incidence and management of lobular carcinoma in situ compared with ductal carcinoma in situ: a Korean breast cancer registry analysis
J. Min, E.T. Kim, M.C. Chang, K.T. Hwang (South Korea)

Outcomes of magseed localisation of non-palpable breast lesions in a large university hospital
A. Gaber, M. Al-Attar, S. Pilgrim, M. Hoosein, M. Kaushik (United Kingdom)

A human-derived acellular dermal matrix for breast reconstruction: The first European experience
F. Marongiu, D. De Tullio, D. Tognali, P.ensor, S. Pasquali, A. Sibilio, R. Sgarzani, M. Mingozzi, F. Buggi, A. Curcio (Italy)

Young age as an independent prognostic factor in breast cancer

Do surgical margins matter after mastectomy? A systematic review and meta-analysis
J. Bundred, S. Michael, S. Bowers, N. Barnes, Y. Jauhari, D. Plant, T. Maishman, R. Cutress, B. Holleczek, D. Dodwell, N. Bundred (United Kingdom)

Axillary management in patients with breast cancer and positive axilla at diagnosis
M. Jimenez Gomez, V. Vega Benitez, I. Gutierrez Giner, P. Pérez Correa, J.R. Hernández Hernández (Spain)

Accuracy of Magnetic Localisation device placement and retrieval in breast cancer patients from a single internationally Accredited Breast Centre in Johannesburg South Africa
C. Benn, V. Shaw, P. Ilunga, F.Z. Rahman, A. Jogee, J. Belloni (South Africa)

Short-term outcome and complications rate after immediate breast reconstruction with implants and acellular dermis
V. Bjelic-Radisic, E. Kirchhoff, C. Leidl, E. Trapp, D. Ulrich (Germany)
<table>
<thead>
<tr>
<th>DOI</th>
<th>Title</th>
<th>Authors/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB-087</td>
<td>The enduring rise of the contralateral prophylactic mastectomy: population trends in Ontario, Canada</td>
<td>L. Findlay-Shirras, I. Lima, G. Smith, M. Clemons, J. Hilton, A. Amaout (Canada)</td>
</tr>
<tr>
<td>PB-091</td>
<td>Symptomatic presentation and involved margins lead to Ductal Cancer In Situ recurrence</td>
<td>S. Michael, S. Bowers, J. Ooi, M. Absar, S. Ellenbogen, N. Bunded (United Kingdom)</td>
</tr>
<tr>
<td>PB-092</td>
<td>Magseed localisation for loco-regional breast and lymph node recurrences. Placement prior to chemotherapy allows focused removal of the initially diseased tissue</td>
<td>C. Benn, V. Shaw, P. Ilunga, A. Jogee, D. Van Logerenberg (South Africa)</td>
</tr>
<tr>
<td>PB-093</td>
<td>Innovative magnetic tracers for sentinel node detection in primary breast cancer surgery and after neoadjuvant therapy</td>
<td>K. Rauš, A. Faridová (Czech Republic)</td>
</tr>
<tr>
<td>PB-094</td>
<td>Did the BOOG 2013-08, which examines the value of omission of the sentinel lymph node in cT1-2 breast cancer treated with BCT, induce a change in axillary staging and treatment?</td>
<td>E. Colier, S. Pessers, R. Vos, M. Smidt, L. Van Roozendaal (Netherlands)</td>
</tr>
<tr>
<td>PB-095</td>
<td>Endofacial axillary dissection - a novel method to reduce seroma formation</td>
<td>S. M. P. Augustine, R. Bhargavan, K. Cherian, S. S (India)</td>
</tr>
<tr>
<td>PB-096</td>
<td>How many sentinel lymph nodes in addition to the clipped node are needed to accurately stage the axilla after neoadjuvant treatment in breast cancer?</td>
<td>C. Siso, A. Esgueva, J.P. Salazar, M. Espinosa-Bravo, I.T. Rubio (Spain)</td>
</tr>
<tr>
<td>PB-097</td>
<td>Risk of contralateral breast cancer and ovarian cancer in BRCA1 founder mutation (5382insC or 4154delA) carriers with primary breast cancer</td>
<td>P. Loza, A. Imrejs, J. Maksimenko, G. Trofimovics, J. Gardovskis, E. Miklasevics, Z. Daneberga (Latvia)</td>
</tr>
<tr>
<td>PB-098</td>
<td>Safety, feasibility and clinical outcomes of robotic nipple sparing mastectomy: A systematic review of the literature</td>
<td>T. Cil, F. Angarita, M. Castelo, D. McCready, M. Englesakis (Canada)</td>
</tr>
<tr>
<td>PB-099</td>
<td>The role of cryoablation in patients with metastatic breast cancer at the time of presentation</td>
<td>A. Fancellu, L. Melis, N. Balliciu, P. Meloni, V. Sanna, A. Porcu, C. Pusceddu (Italy)</td>
</tr>
<tr>
<td>PB-100</td>
<td>Direct or delayed oncoplastic reconstruction after wide local excision for breast cancer in breast conserving therapy: A single centre cohort study of 252 cases</td>
<td>C.S. Geluk, A. Van Loovezijn, M.J.T.F.D. Vrancken Peeters, F.H. Van Duijnhoven, M.J. Hoornweg (Netherlands)</td>
</tr>
<tr>
<td>PB-101</td>
<td>Importance of intraoperative surgical margin assessment for positive margin diagnosis in breast cancer-conserving surgery</td>
<td>A. Goikoetxea Urdiain, P. Arriandariz Rubio, N. Moras Pérez, C. Artieda Soto, S.D.P. Miguel Angel, V.P. Leyre (Spain)</td>
</tr>
<tr>
<td>PB-102</td>
<td>Axillary staging with supine 18F-FDG PET/CT is useful in breast cancer patients undergoing tailored axillary treatment after neoadjuvant systemic therapy according to the MARI protocol</td>
<td>A. Van Loovezijn, M.L. Donswijk, M.P.M. Stokkel, F. Van Duijnhoven, M.J.T.F.D. Vrancken Peeters (Netherlands)</td>
</tr>
</tbody>
</table>

PB-104 Realising true day-case breast surgery: A review of factors influencing same-day discharge (SDD) T. Chouari, K. Rangarajan, H. Osman, R. Daoud, I. Laidlaw, M. Uhercik, I. Karat (United Kingdom)

PB-105 Nipple sparing mastectomy (nsm) after surgical delay (sd) and prepectoral direct to implant (dti) reconstruction with polyurethane prostheses: preliminary results A. Loreti, B. Fanelli, D. Spallone, F. Arelli, M. Marcasciano, O. Abate, C. Latini, M. De Carli, M. La Pinta, E. Manna, E. Zarba Meli, L. Fortunato (Italy)


PB-107 MRI prediction of response to neoadjuvant chemotherapy in breast cancer: comparison between patients with and without mammographic calcifications E. Carmon, B. Simor, B. Mali, T. Sella (Israel)

PB-108 Definitive treatment of premalignant lesions of the breast with "double crown": An innovative percutaneous technique O. Aparicio, M. Medarde, A. Martin, L. Tortajada, J. Del Riego, M. Sentis, S. Navarro (Spain)

PB-109 Automatic detection of perforators for microsurgical reconstruction and correlation with patient's body-mass index D. Pinto, C. Mavioso, R. J. Araujo, H. P. Oliveira, J. C. Anacleto, M.A. Vasconcelos, P. Gouveia, N. Abreu, C. Alves, J. S. Cardoso, M.J. Cardoso, F. Cardoso (Portugal)

Poster Session: Nursing

PB-110 Clinical decision trees provide a means for systematic registration and evaluation of multidisciplinary team recommendations M. Hendriks, X. Verbeek, J. Van Manen, S. Van der Heijden, S. Go, G. Gooiker, T. Van Vegchel, S. Siesling, A. Jager (Netherlands)


PB-113 Process evaluation of the bridging the age gap in breast cancer decision support intervention cluster randomised trial M. Burton, K. Lifford, L. Wyld, F. Armitage, K. Collins, M. Reed, K. Brain, A. Edwards (United Kingdom)

PB-114 Improving pain outcomes after breast cancer surgery using a novel psychoeducational intervention M. Alwan, S. Down (United Kingdom)

Poster Session: Supportive and Palliative Care Including End of Life Treatment

PB-115 Clinical decision trees provide a means for systematic registration and evaluation of multidisciplinary team recommendations M. Hendriks, X. Verbeek, J. Van Manen, S. Van der Heijden, S. Go, G. Gooiker, T. Van Vegchel, S. Siesling, A. Jager (Netherlands)


PB-118 Process evaluation of the bridging the age gap in breast cancer decision support intervention cluster randomised trial M. Burton, K. Lifford, L. Wyld, F. Armitage, K. Collins, M. Reed, K. Brain, A. Edwards (United Kingdom)

PB-119 Improving pain outcomes after breast cancer surgery using a novel psychoeducational intervention M. Alwan, S. Down (United Kingdom)
The Effect of Scalp-Cooling System on the Prevention of Alopecia after chemotherapy

Use of an Alfa-lipoic, Methylsulfonylmethane, Boswellia Serrata and Bromelain Dietary Supplement for Aromatase Inhibitors-related Arthralgia Management (AIA): a prospective phase II trial (NCT04161833)
I. Desideri, S. Lucidi, P. Garfatti, V. Lorenzetti, C. Ciabatti, F. Terziani, V. Scotti, P. Bonomo, G. Francolini, I. Meattini, L. Livi (Italy)

Distress and effectiveness of Brief Cognitive Behaviour Intervention for patients with family history of cancer
J. Srivastava, S. Kaushik, H. Shukla (India)

Theory of mind deficit in women with breast cancer and depression: a comparative study from India
S. Ostwal, A. Datta (India)

The effect of a chamomile compound on pain and heaviness in breast cancer patients with Lymphedema: a double-blind and randomized controlled trial

Symptom talk during clinic visits for treatment of breast cancer: do we get an accurate picture?
K. Mooney, Professor, M. Whisenant (USA)

Variation and efficacy of scalp cooling in Dutch hospitals among >5000 breast cancer patients
C. Van Den Hurk, W. Dercksen, B. Vriens, H. Nortier, W. Breed (Netherlands)

Administration of LHRH agonist as an adjuvant endocrine therapy for breast cancer is a risk factor of ovarian function recovery after switching from tamoxifen to aromatase inhibitor
H. Ishige (Japan)

Finding existing drugs potentially active against BRCA-mutated breast cancers: a literature-based approach
S. Crispino, P. Pantziarka, L. Meheus, G. Bouche (Belgium)

Dynamic monitoring of CD45+/CD31+/DAPI+ circulating endothelial cells aneuploid for chromosome 8 during neoadjuvant chemotherapy in locally advanced breast cancer
G. Ma, T. Xia, X. Wang (China)

Real-life use of 21-gene signature: A retrospective analysis of 46 cases from private practice
C. Bernard Marty, Mrs., J. Farnarier, L. Puyuelo, J. Capdet, S. Bringer, M. Martinez (France)

Should chemotherapy in neoadjuvant setting in node positive breast cancers be guided by biology over magnitude of tumour burden?
E. Provenzano, E. Garreffa, P. Wignarajah, N. Borkar, V. Psychogiou, A. Newton, J. Benson, P. Forouhi, L. Hughes-Davies, C. Wilson, K. McAdam, S. Russell, A. Agrawal (United Kingdom)

Assessing the benefits and toxicities of platinum containing neoadjuvant chemotherapy in triple negative breast cancer
K. Jarral, K. Kancherla, Z. Arif, S. Sharma, M. Kaushik (United Kingdom)

Effects of chemotherapy on serum lipids in Chinese postoperative breast cancer patients
<table>
<thead>
<tr>
<th>PB-134</th>
<th>Relationship between magnetic resonance imaging of breast and pathological tumor response after neoadjuvant chemotherapy in breast cancer patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>H.J. Lee, H.S. Kim, W.Y. Kim, J.B. Lee, S.U. Woo (South Korea)</td>
<td></td>
</tr>
<tr>
<td>PB-135</td>
<td>Management of early breast cancer by trastuzumab biosimilar: Insights from observational drug utilization registry</td>
</tr>
<tr>
<td>A.D. Dwary (India)</td>
<td></td>
</tr>
<tr>
<td>PB-136</td>
<td>Pyrotinib in HER2-Positive local advanced or metastatic breast cancer patients: results from a retrospective study in real-world setting</td>
</tr>
<tr>
<td>Q. Wang, C. Chen, Y. Wang, S. Sun, J. Cheng (China)</td>
<td></td>
</tr>
<tr>
<td>PB-137</td>
<td>Optimal duration and effectiveness of neoadjuvant endocrine therapy in breast cancer – Retrospective series</td>
</tr>
<tr>
<td>PB-139</td>
<td>The optimal timing and duration of daily filgrastim for primary prevention of febrile neutropenia after TAC chemotherapy: Multicenter randomized open-label phase IV study</td>
</tr>
<tr>
<td>D. Kim, Z. Kim, S.M. Hur, J.E. Lee, S.Y. Kim, C.W. Lim (South Korea)</td>
<td></td>
</tr>
<tr>
<td>PB-140</td>
<td>Compliance to adjuvant endocrine treatment – real world data from 1019 consecutive luminal breast cancer patients with long follow-up</td>
</tr>
<tr>
<td>C. Chamalidou, S. Nasic, B. Linderholm (Sweden)</td>
<td></td>
</tr>
<tr>
<td>PB-141</td>
<td>Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: real life experience.</td>
</tr>
<tr>
<td>PB-142</td>
<td>Pathological Complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer</td>
</tr>
<tr>
<td>S. Jung, C.W. JEON, J. Choi, D. Hyun, H. Lee, K. Kwon, H. Yoon (South Korea)</td>
<td></td>
</tr>
<tr>
<td>PB-143</td>
<td>Mantle cell lymphoma in the context of breast cancer</td>
</tr>
<tr>
<td>A. Vernadou, D. Milowich, J. Bloch, N. Ketterer, L. De Leval, K. Zaman (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>PB-144</td>
<td>A high rate of pathological complete response is possible by incorporating cisplatin in neoadjuvant therapy of locally advanced triple-negative breast cancer: a single-institution experience</td>
</tr>
<tr>
<td>J. Georgy, A. Singh, A. Joel, R. Chacko, A. John, F. Ninan, A. Paul, G. John (India)</td>
<td></td>
</tr>
<tr>
<td>PB-145</td>
<td>Tumor-Infiltrating Lymphocytes: Predictive changes in tumor size after neoadjuvant treatment</td>
</tr>
<tr>
<td>PB-146</td>
<td>Diagnostic performance of noninvasive imaging for assessment of axillary pathologic complete response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis</td>
</tr>
<tr>
<td>PB-147</td>
<td>Quality of life in postmenopausal breast cancer patients with localized disease after 5 years of endocrine treatment: a prospective study</td>
</tr>
<tr>
<td>PB-148</td>
<td>The gene expression profile in clinically node negative T1-2 breast cancer patients: Its additional value in case of sentinel lymph node biopsy is not performed.</td>
</tr>
<tr>
<td>E. Collier, M. Vane, L. Roozendaal, M. De Boer, S. Siesling, M. Smidt (Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>
PB-149  A Predictive Model for Pathologic Complete Response in Breast Cancer Patients treated with Neoadjuvant Chemotherapy using Machine Learning
I. Kim, S.K. Kim, L. Seung Ah (South Korea)

EBCC-12 Scientific programme

Thursday 19 March 2020

Society Session: European Society of Surgical Oncology (ESSO) - Breast Cancer Surgery: Less is More - Simpler is Better

08:00 - 09:30 Picasso

Chair: Isabel T. Rubio (Spain)
Chair: Tibor Kovacs (United Kingdom)

08:00 Risks of overdoing in breast cancer
Speaker: Maria João Cardoso (Portugal)

08:18 Q & A

08:23 Surgical management of local recurrences in breast cancer
Speaker: Oreste Gentilini (Italy)

08:41 Q & A

08:46 Is overexploring and overtreating the axilla avoidable?
Speaker: Peter Dubsky (Switzerland)

09:04 Q & A

09:09 Certification in breast surgical oncology and oncoplastics
Speaker: Tibor Kovacs (United Kingdom)

09:27 Q & A

Teaching Lecture: New Trends in Radiation Therapy

08:30 - 09:00 Goya

08:30 New Trends in Radiation Therapy
Speaker: Charlotte E. Coles (United Kingdom)

Teaching Lecture: Counselling Healthy Carriers with High Moderate and low Penetrance Genes

09:00 - 09:30 Goya

09:00 Counselling Healthy Carriers with High Moderate and low Penetrance Genes
Speaker: D.M. Eccles (United Kingdom)
Describe genetic landscape for inherited breast cancer risk
Explore different elements that contribute to risk perception
Describe approaches to risk stratified management
Teaching Lecture: Early Triple-ve
08:30 - 09:00 Miro

09:00 Early Triple-ve
Speaker: Alessandra Gennari (Italy)

Teaching Lecture: Early HER2+ve
09:00 - 09:30 Miro

09:00 Early HER2+ve
Speaker: Javier Cortés (Spain)

Clinical Science Symposium: Artificial Intelligence in Breast Cancer Care
10:00 - 11:30 Picasso
Chair: Maria João Cardoso (Portugal)
Chair: Paola Mosconi (Italy)

10:00 Surgery
Speaker: Maria João Cardoso (Portugal)

10:15 Imaging
Speaker: Ritse Mann (Netherlands)

10:30 Pathology
Speaker: Hugo Horlings (Netherlands)

10:45 Implementation of clinical decision support systems for breast cancer treatment
Speaker: Brigitte Seroussi (France)

11:00 Patient perspective
Speaker: Vesna Ramljak (Croatia)

11:15 Challenges in implementing AI for population breast cancer screening
Speaker: Nehmat Houssami (Australia)

Multidisciplinary Team in the Real World: Optimal Management of Brain Metastasis
10:00 - 11:00 Goya
Moderator: Volkmar Mueller (Germany)

Radiation oncologist
Panel: Barbara Jereczek (Italy)

Medical oncologist
Panel: Thomas Bachelot (France)

Neurosurgeon
Panel: Philippe Metellus (France)
Society Session: European Society of Breast Imaging (EUSOBI) - Case-Based Radiologic-Pathologic Correlation

10:00 - 11:30

Moderator: Karen Kinkel (Switzerland)
Moderator: Tibor Tot (Sweden)

DCIS
10:00 Radiologist
Speaker: F Pediconi (Italy)
1. To learn about different types of DCIS.
2. To become familiar with different imaging appearances of DCIS.
3. To appreciate radiologic-pathologic correlations.

10:15 Pathologist
Speaker: G D’Amati (Italy)
Learn about the gross and histologic features of DCIS
Learn about correlations between pathologic features and imaging
Be aware of potential pitfalls

10:30 Discussion
Neoadjuvant treatment response evaluation

10:45 Radiologist
Speaker: Julia Camps-Herrero (Spain)

11:00 Pathologist
Speaker: Laia Bernet Vegue (Spain)

11:15 Discussion

Debate: This House Supports Breast Cancer Screening Based on Population age Rather than Specific Risks
11:45 - 12:45

Co-Moderator: Robert E. Mansel (United Kingdom)
Co-Moderator: Elizabeth Bergsten-Nordstrom (Sweden)

11:45 Speaker in favour: Jonas Bergh (Sweden)
12:00 Speaker against: Gareth Evans (United Kingdom)
12:15 Seconder in favour: David A. Cameron (United Kingdom)
12:25 Seconder against: Harry J. De Koning (Netherlands)
12:35 Voting/Conclusion

Best Practice Session: The Management of Young Patients
11:15 - 12:15  
**Dali**

Chair: Olivia Pagani (Switzerland)  
Chair: Tanja Spanic (Slovenia)

11:15  **Fertility**  
Expert: Matteo Lambertini (Italy)

11:25  **Pregnant patients**  
Expert: Sibylle Loibl (Germany)

11:35  **Endocrine therapy**  
Expert: Olivia Pagani (Switzerland)

*Nurse (Panel member)*  
Expert: Gillian Howard Jones (United Kingdom)  
*Patient (Panel member)*  
Expert: Tanja Spanic (Slovenia)

11:45  **Panel discussion**

**EUROPA DONNA Session: Strategies for women with MBC: What we are learning**

11:45 - 12:45  
**Goya**

Chair: Karen Benn (Italy)  
Chair: Biljana Dodeva (Macedonia)

11:15  **Oncologist perspective/ABC alliance**  
Speaker: Fátima Cardoso (Portugal)

11:30  **New research on importance of exercise regime for women with MBC-PREFERABLE**  
Speaker: Anne May (Netherlands)

11:45  **European MBC advocacy education and surveys on return to work**  
Speaker: Karen Benn (Italy)

11:55  **National Programme Italy: FORTEMENTE - Psychological support for women with MBC**  
Speaker: Rosanna Fidanzia - D'Antona (Italy)

12:05  **Discussion**

**Poster in the Spotlight: Poster in the Spotlight II**

13:30 - 14:00  
**Poster Area/Exhibition Hall**

PB-004  **Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases**  
*Moderated discussion*

PB-005  **Real-world analysis of patients’ clinical and geriatric characteristics aged ≥ 70 years with advanced breast cancer receiving palbociclib with endocrine therapy in the French cohort PALOMAGE**  
E. Brain, J. Grosjean, M. Pulido, E. Paillaud, E. Carola, N. Jovenin, O. Guillem, M. Chehimi, W. Mina, P. Caillet, L. Tassy, C. Falandry, N. Rifi, J.M. Vauthier (France)  
*Moderated discussion*
Moderated discussion

**PB-006**

Gut microbial short chain fatty acids are associated with pathological complete response (pCR) after neoadjuvant chemotherapy for breast cancer

K. Ross, R. Papadopoulou, B. Nichols, M. Macleod, J. Fraser, S. Barrett, J. Evans, K. Gerasimidis, I. Macpherson (United Kingdom)

**Moderated discussion**

**Multidisciplinary Team in the Real World: Local Relapse After Breast Conservation**

14:45 - 15:45  

**Dali**

Moderator: Frederieke Van Duijnhoven (Netherlands)

**Medical oncologist**
Panel: Joana Ribeiro (Portugal)

**Radiation oncologist**
Panel: Icro Meattini (Italy)

**Radiologist**
Panel: Francesco Sardanelli (Italy)

**Educational Session: Antibody Drug Conjugates: Optimising Drug Delivery**

14:45 - 15:45  

**Goya**

Chair: David A. Cameron (United Kingdom)

14:45 **Mechanisms of action of ADCs**
Speaker: Matthias Peipp (Germany)

15:05 **ADCs - Targeting HER family**
Speaker: Junji Tsurutani (Japan)

15:25 **Discussion**

**Proffered Paper Session: Proffered Papers Session**

14:45 - 15:45  

**Picasso**

Chair: Javier Cortés (Spain)

**Predictors of efficacy in patients (pts) with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2–ABC): subgroup analyses of PALOMA-3**
Oral Abstract SP: Hope Rugo (USA)

**Chemoprevention for breast cancer: A survey of the views of Australian women and clinicians**
Oral Abstract SP: Courtney Macdonald (Australia)

**Screen-detected breast cancers have different tumor biology and better prognosis compared to interval breast cancers**
Oral Abstract SP: Josephine Lopes Cardozo (Belgium)
Young Investigators Session: Interactive Lecture on Publishing Your Research
14:45 - 15:45  
Room 129-130

Information and interactive discussion under the guidance of two Editors from (breast) oncology journals on tips and tricks regarding how to get your paper published.
Moderator: Fátima Cardoso (Portugal)
Moderator: Suzette Delaloge (France)

Clinical Science Symposium: Preoperative Systemic Therapy: How do we Respond to the Response?
16:15 - 17:45  
Picasso

Chair: Emiel J. T. Rutgers (Netherlands)
Chair: Susan Knox (Italy)
16:15  
Systemic therapy
Speaker: Michael Untch (Germany)
neoadjuvant therapy
postneoadjuvant therapy
targeted therapy

16:30  
Surgery
Speaker: Marie Jeanne Vrancken - Peeters (Netherlands)

16:45  
Radiation oncology
Speaker: Philip Poortmans (Belgium)

17:00  
Pathology
Speaker: Frédérique Penault-Llorca (France)

17:15  
Psychology
Speaker: Luzia Travado (Portugal)

17:30  
Minimally Invasive Complete Response Assessment of the breast after neoadjuvant systemic therapy (MICRA trial): interim analysis of a multicenter observational cohort study
Oral Abstract SP: F.H. Duijnhoven (Netherlands)

Clinical Science Symposium: Implants
16:15 - 17:45  
Dali

Chair: Christoph Heitmann (Germany)
Chair: Nicole Zemik (France)
16:15  
Are they safe?
Speaker: Frederieke Hagemann (Germany)

16:30  
When and where
Speaker: Christoph Heitmann (Germany)

16:45  
Best imaging with implants
Speaker: Eva Fallenberg (Germany)

17:00  
Radiation oncology
Speaker: Orit Kaidar-Person (Israel)
17:15 **Pathology**  
Speaker: Philippe Gaulard (France)

17:30 **Safety of pre-pectoral breast reconstruction followed by post mastectomy radiotherapy**  
Oral Abstract SP: M. Bernini (Italy)

**Society Session: EUSOMA - Breast Centres Certification (BCCERT) - Breast Centre: Challenges in Quality of Care**

16:15 - 17:45  
Goya

Chair: Isabel T. Rubio (Spain)

16:15 **Evidence of the benefits of multidisciplinary approach in 2020**  
Speaker: Luigi Cataliotti (Italy)  
*Improving Survival, Quality of Care, Quality of Life*

16:35 **Updating in Qls trend**  
Speaker: Antonio Ponti (Italy)

16:50 **Work in progress: Quality indicators in metastatic breast cancer care**  
Speaker: Fátima Cardoso (Portugal)

17:05 **The requirements of a specialist Breast Centre: the new Eusoma document endorsed by ECCO and ESMO**  
Speaker: Laura Biganzoli (Italy)  
- Present requirements in offering quality of care to breast cancer patients  
- Reinforce the concept of multidisciplinarity  
- Point out the importance of having patient-centered pathways that cover the entirety of the breast cancer course

17:20 **Clinical research in a Breast Centre**  
Speaker: Olivia Pagani (Switzerland)

17:35 **Discussion**

**Young Investigators Session: Lecture on Funding Your Research**

16:15 - 17:00  
Room 129-130

Tips and tricks from a senior expert on where to look for funding, your application, etc. with a focus on smaller grants.

16:15 **Requesting grants**  
Speaker: Jelle Wesseling (Netherlands)

16:25 **Perspective of the grant selection committee**  
Speaker: David A. Cameron (United Kingdom)  
Interactive Discussion

**Young Investigators Session: Basics of Statistics**

17:00 - 18:00  
Room 129-130
An educational session on the most important statistical principles that young investigators should know to be able to have a good critical view on the research presented at conferences and in papers

Moderator: Coralie Poncet (Belgium)

Topics

Trial phases and possible design (incl. discussion on randomization, blinding)

Choice of primary endpoint (incl. discussion on time to event endpoints, importance of schedule assessment, which endpoints are most clinically relevant; a significant p-value does perhaps not always mean a significant gain for a patient, eg. a 2 month difference; do we call this a success?)

Fundamentals on hypothesis testing (including discussion on type 1 error, power, clinical vs stats significance)

Ingredients of sample size calculation

Poster Session: Advanced Disease

PB-007 The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients

PB-008 An exploratory phase II study of Eribulin re-challenge after short term therapy of 5-fluorouracil for HER2-negative, advanced or recurrent breast cancer

PB-009 Characteristics of metastatic breast cancer patients obtaining a clinical complete response with systemic therapies
Y. Horimoto, R. Sasaki, K. Nakai, K. lijima, M. Saito (Japan)

PB-010 Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: an exploratory cohort study

PB-011 Does Neo-adjuvant chemotherapy response in the primary breast tumour correlate with axillary response in proven node positive ER positive HER2 negative disease?
N. Borkar, E. Provenzano, E. Garreffa, J. Benson, P. Forouhi, L. Hugh-Davies, C. Wilson, K. McAdam, S. Russell, A. Agrawal (India)

PB-012 Treatment with eribulin could suppress epithelial-mesenchymal transition (EMT) characteristics in tumors of patients with metastatic breast cancer
T. Utsumi, T. Hayashi, N. Kobayashi, M. Hikichi, K. Ushimado, S. Nakano, K. Fujii, T. Ando (Japan)

PB-013 Compared expression of Tumour Infiltrating Lymphocytes and FOXA1 in matched pairs of brain metastasis and primary breast cancer and prognostic implications – a pilot study
A. Thulin, E. Rönneman, S. De Lara, C. Chamalidou, A. Schoenfeldt, A. Kovács, B. Linderholm (Sweden)

PB-014 Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer (ABC) in Asia and Middle East (ME): Results from the Count Us, Know Us, Join Us (CUKUJU) survey
A. Ripley, J. Lehr, M. Shaalan, S. Koppikar, V. Gupta, M. Gao, N. Abdelbaky, F. Cardoso (USA)
PB-015 Neutrophil to lymphocyte ratio (NLR) may predict survival and efficacy of eribulin in advanced breast cancer patients
Y. Haruyama, E. Fukuma, O. Yu, Y. Koshida, N. Sakamoto, A. Gen, R. Nakagawa, M. Nashimoto, M. Sakamoto, K. Teraoka, M. Nakagawa (Japan)

PB-016 Use of indocyanine green (ICG) alone as a tracer for sentinel lymph node detection after neoadjuvant chemotherapy in breast cancer patients
F. Cattin, MD, T. Fogacci, G. Frisoni, G. Semprini, L. Fabiocchi, D. Samorani (Italy)

PB-017 Breast cancer patients with leptomeningeal carcinomatosis: Treatment results and validation of prognostic indexes
I. Ratosa, T. Znidaric (Slovenia)

PB-019 Treatment efficacy and predictors of durable response to capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort
S. Thijsen, H. Wildiers, K. Punie, B. Beuselinck, P. Berteloot, S. Han, E. Van Nieuwenhuysen, T. Van Gorp, I. Vergote, P. Neven (Belgium)

PB-020 Cyclin-dependent kinase 4/6 inhibitors palbociclib or ribociclib combined with endocrine therapy and radiation therapy for patients with metastatic breast cancer
I. Ratosa, E. Scoccimarro, L. Dominici, M. Orazem, M. Steinacher, M. Aquilano, C. Cerbai, I. Desideri, T. Marinico, L. Livi, I. Meattini (Italy)

PB-021 Real-World data of triplet combination of trastuzumab, lapatinib and chemotherapy in HER2-positive metastatic breast cancer: a multi-center retrospective study
Y. Li, C. Gong, Q. Lu, Z. Zhou, T. Luo, W. Li, G. Li, R. Ge, B. Wang (China)

PB-022 Impact of Ki67 and progesterone receptor on PFS with cyclin-dependent kinase 4/6 inhibitors in HER2-negative advanced breast cancer: a real world mono-institutional experience
M. Palleschi, E. Barzotti, E. Melegari, S. Manunta, F. Mannozzi, A. Vagheggini, R. Maltoni, A. Fedeli, S. Sarti, L. Cecconetto, A. Rocca (Italy)

PB-023 Improved QTcF diagnostic using tele-cardiology
L.S. Fink, Y. Patel, T. Schinköthe (Germany)

PB-024 Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the Ballet study
S. Corona, F. Giudici, G. Jerusalem, E. Ciruelos, C. Strina, O. Bernocchi, M. Milani, M. Dester, N. Ziglioli, G. Barbieri, V. Cervoni, F. Montemurro, D. Generali (Italy)

PB-025 HLX02, a China-manufactured Trastuzumab Biosimilar Versus EU-sourced Trastuzumab: Results of a Global Phase 3, Randomized, Double-blind Efficacy and Safety Comparative Study in Metastatic Breast Cancer

PB-026 Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system

PB-027 Time to first health care contact, referral pathways and stage at presentation – the experience from four South African breast units
C. Pothas, S. Nieuw, T. Oluwa, M. Witness, H. Cubasch, M. Joffe (South Africa)

Poster Session: Advocacy
Poster Area/Exhibition Hall

PB-028 Women's descriptions six months post notification of positive BRCA 1/2 genetic mutations
M. Becker (USA)
<table>
<thead>
<tr>
<th>Poster Session: Basic Science and Translational Research</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PB-033</strong> Interverplay between the Pan-Tumor Suppressor miR-939-5p and the oncogenic IncRNA-HEIH dually curbs Hydrogen Sulphide and Nitric Oxide production in breast cancer cells</td>
<td>275</td>
</tr>
<tr>
<td>H. Nafea, R. Youness, K. Abou-Aisha, M. Gad (Egypt)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-035</strong> miR-486-5p and miR-17-5p: Novel Immunomodulatory Non-coding RNAs Drawn Downstream 3’-O-Acetyltyisoxanthin in Triple Negative Breast Cancer</td>
<td>277</td>
</tr>
<tr>
<td>A. Elkhouly, R. Youness, A. Abdelmotaal, M. Gad (Egypt)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-036</strong> Methylation of the NT5E gene, encoding for CD73: prognostic significance in breast cancer</td>
<td>278</td>
</tr>
<tr>
<td>Y.J. Jeong, H.K. Oh, H.R. Choi, S.H. Park (South Korea)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-037</strong> impact of CDK4 knock out using CRISPR/Cas9 gene editing technology on breast cancer progression</td>
<td>279</td>
</tr>
<tr>
<td>A. Ahmed, D. Ashraf, A. Bahaa, H. El-Rayabi, H. Adwan (Egypt)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-038</strong> Inverse association between IFN-γ level released from NK cell and breast cancer stage</td>
<td>280</td>
</tr>
<tr>
<td>J.I. Kim, E. Um (South Korea)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-039</strong> Multi-targeting antibody to control proliferation, metastasis and angiogenesis in mammary gland tumors</td>
<td>281</td>
</tr>
<tr>
<td><strong>PB-040</strong> Computerized scoring tool for identification and quantification of different immune cell populations in breast tumor regions</td>
<td>282</td>
</tr>
<tr>
<td>L. Berben, H. Wildiers, C. Kenis, B. Dalmasso, A. Smeets, H. Vos, P. Neven, L. Marcelis, A. Antoranz-Martinez, F. Bosisio, G. Floris, S. Hatse (Belgium)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-041</strong> Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information</td>
<td>283</td>
</tr>
<tr>
<td>C.A. Frisell, J. Lagergren, M. Halle, J. De Boniface (Sweden)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-042</strong> Socioeconomic status influences immediate breast reconstruction rates, patient information and involvement in surgical decision-making</td>
<td>284</td>
</tr>
<tr>
<td>C.A. Frisell, J. Lagergren, M. Halle, J. De Boniface (Sweden)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-043</strong> Evaluation of circulating cell-free DNA and its integrity as a potential predictive biomarker of breast cancer onset: a pilot study</td>
<td>285</td>
</tr>
<tr>
<td>B. Scaggiante, F. Giudici, F. Zanconati, C. Bottin, C. Revoltella, S. Corona, M. Cappelletti, D. Generali, M. Bourli (Italy)</td>
<td></td>
</tr>
<tr>
<td><strong>PB-044</strong> PIK3CA mutations and predicting the therapeutic effects of neoadjuvant chemotherapy in primary breast cancer</td>
<td>286</td>
</tr>
</tbody>
</table>
| PB-045 | Project PRIMO – Combining Patient Derived Breast Cancer Microtumors and DigiWest protein signaling pathway profiling for therapeutic response prediction  
N. Anderle, F. Ruoff, A. Koch, A. Hartkopf, S. Brucker, M. Templin, C. Schmees (Germany) |
| 287 |
| PB-046 | Verification of metabolic competition mechanisms in androgen receptor-positive triple negative breast cancer  
| 288 |
| PB-047 | Clinical correlation between Programmed Cell Death Ligand One (PD-L1) Expression, Tumor Infiltrating Lymphocytes (TILs) and pathological response of locally advanced Human Epidermal Receptor (HER 2) & Triple Negative (TN) Breast Cancer (BC) Egyptian patients undergoing neoadjuvant Therapy  
E. Shash, E. Khorshed, A. Namour, E. El Desouky, A. Bahnassy, N.M.A. Allahloubi (Egypt) |
| 289 |
| PB-048 | Plasma markers showing differential baseline expression in relapsing versus non-relapsing patients with hormone sensitive breast tumors  
S. Halse, Y. Lambrechts, K. Punie, G. Floris, L. Berben, A. Laenen, D. Lambrechts, C. Desmedt, C. Weltens, A. Sneeuws, C. Van Ongeval, P. Neven, H. Wildiers (Belgium) |
| 290 |
| PB-049 | The value of uPA and PAI-1 levels in triple negative breast cancer  
M. Sobocan, Z. Ledinek, B. Crnobilj, N. Čas Sikošek, N. Fokter Dovnik, R. Kavalar, J. Knez, I. Takač (Slovenia) |
| 291 |
| PB-050 | Integration of genomic profiling and functional screening identifies potential driver somatic copy number alterations in triple-negative breast cancer  
G. Xie, X. Xu (China) |
| 292 |
| PB-052 | Patient-assisted vs standard compression mode in mammography screening: A randomized clinical trial  
E.N. Arenas Rivera, M. Posso, M. Pitarch, P. Nicolau Batalla, M.D.M. Vernet, R. Alcantara Souza (Spain) |
| 294 |
| PB-053 | Prognostic utility of androgen receptor signaling pathway in invasive breast cancer  
| 295 |
| PB-054 | Axillary lymph node involvement may be predicted by breast cancer subtype: a single center experience.  
G. Cistermino, G. Dajti, A. Pellegrini, M. Serra, S. Zanotti, C. Ceccarelli, D. Santini, M. Taffurelli (Italy) |
| 296 |
| PB-055 | Micro-morphological regression patterns of tumors and lymph nodes following neoadjuvant chemotherapy for breast cancer with follow-up analysis: a new scoring system with implication into practice  
M. Śniadecki, M. Orłowska-Volk, T. Erbes, E. Wycinka, M. Werner (Germany) |
| 297 |
| PB-056 | Relationship between VEGF-A and PD-L1 expression in primary breast cancer  
| 298 |
| PB-057 | Molecular subtypes and outcomes of different breast cancer histologies  
E. Beh, A. Raman, R.Y.C. Tan, W.S. Ong, V. Tan, J. Iqbal, F.Y. Wong, Y.S. Yap (Singapore) |
| 299 |
| PB-058 | Pre-clinical and clinical development of lead molecule (IM522) against Paclitaxel non-responsive TN Breast Cancers  
F. Malik (India) |
| 300 |
| PB-059 | Gene expression profiles in premenopausal women with HR+ HER2- early breast cancer  
H. Ni, A. Kurt, J. Kumbrink, A. Seiler, D. Mayr, T. Degenhardt, F. Hagemann, R. Würstlein, N. Harbeck, T. Eggersmann (Germany) |
| 301 |
| PB-060 | Circulating tumor associated cells in breast cancers are resistance educated towards prior anthracycline treatments.  
| 302 |
| PB-061 | Real-time non-invasive chemoresistance profiling of circulating tumor associated cells in breast cancers to determine resistance towards mitotic inhibitors .  

BRCA variant classification of ClinVar submitter content from ENIGMA, ARUP laboratories and German cancer consortium compared to MH BRCA® and correlation with response to PARP inhibition in MH GUIDE®


Interaction of PAFAH and beta-catenin in BRCA1 mutant breast cancer


A Breast 3D model as a possible tool for non-invasive tumour localization in breast surgery


Application of culture-based assays to human malignant breast tissue can infer tumour microbiota composition


Characterization of 331G/A polymorphism of rp gene and identification of viral oncogene hmtv virus as genetic markers for the improvement of breast cancer management in Cameroon

N. Nguedia Kaze (Cameroon)

circRNA Expression in serum exosome in breast cancer

S. Kolahdouzan (Iran)

Non-BRCA hereditary gene mutations in the Mongol breast cancer patients of Russia

P. Gervas, E. Denisov, A. Kiselev, A. Molokov, A. Ivanova, E. Choyzonon, N. Cherdyntseva (Russian Federation)

Association of germline genetic variants with breast cancer survival in patient subgroups defined by standard clinic-pathological variables

A. Morra, M. Escala-Garcia, S. Canisius, R. Keeman, M. Garcia-Closas, P.D.P. Pharoah, M.K. Schmidt (Netherlands)

Rates of contralateral breast cancer amongst patients with non-BRCA germline mutations

B. Murphy, P. Nobecourt, M. Yi, B. Arun, A. Gutierrez, I. Bedrosian (USA)

Clinical outcomes according to BRCA status in breast cancer patients: could the BRCA mutation be used as a prognostic factor?

N. Park, J.E. Lee, Z. Kim, S.M. Hur (South Korea)

Prevalence of germline BRCA pathogenic variants in a monoinstitutional cohort of patients with triple negative breast cancer


Clinical pathological association with breast cancer gene analysis through next generation sequencing

S. Jung, C.W. Jeon, J. Choi, D. Hyun, H. Lee, K. Kwon, H. Yoon (South Korea)

New germline RAD51D gene variant in the Mongol breast cancer patients

A. Molokov, P. Gervas, N. Cherdyntseva (Russian Federation)

Use of multi gene-panel testing to detect hereditary breast cancer gene variants in patients attending to a breast cancer clinic, Peradeniya, Sri Lanka

L. Yatawara, D. Jayasooriya, G. Hettiarachchi, B. Hewavithana (Sri Lanka)
PB-076  The risk of colorectal cancer associated with BRCA 1 and/or BRCA 2 mutation carriers: systematic review and meta-analysis

PB-077  BRCA screening among Jewish community of Rome
L. De Marchis, A. Minucci, A. Gelibter, G. Mazzuccato, V. Magri, G. Moscati, R. Madaio, P. Marchetti, A. Urbani, E. Cortesi, E. Capoluongo (Italy)

Poster Session: Lifestyle, Prevention including Secondary Prevention

Poster Area/Exhibition Hall

PB-078  Five-year follow-up results of aerobic and circuit training on bone mineral density in early breast cancer patients

PB-079  Age-, community-matched Body Mass Index and overall survival in patients with breast cancers
J. Lee, S. Park, M. Oh (South Korea)

PB-080  An audit of chemoprevention provision in a breast cancer family history clinic
A. Patel, K. Foster (United Kingdom)

PB-081  Is socioeconomic status a barrier for individual breast cancer awareness in developing countries?
A. Giri Sarkar (India)

PB-082  Getting fit for surgery: introducing a multi-modal prehabilitation programme for our breast surgical patients
F. Wu, R. Laza-Cagagias, A. Pagarkar, M. El Gammal, T. Rampal (United Kingdom)

PB-083  The effects of lifestyle modification, including dietary and physical activity interventions, on Anthropometric indices and Quality of life of patients with breast cancer: A systematic review and meta-analysis of clinical trials
E. Razmpoosh, A. Sajadian, S. Vafa, M. Zarrati, M. Raji, A. Salehi-Abargouei (Iran)

PB-084  Muscle quality is a prognostic factor for postoperative complications after DIEP-flap breast reconstruction
N. Sadok, H. Michelle, A. Viddeleer, J. Klaase, P. Werker, G. De Bock, L. Jansen (Netherlands)

T. Mulliez, K. Barbé, M. De Ridder (Belgium)

PB-086  Quality of life (QoL) post surgical treatment of breast carcinoma: a prospective study
E. Palma, G. Rizzo, S. Papi, F. Combi, S. Fenocchi, G. Tazzioli, R. Massa (Italy)

Poster Session: Local Regional Treatment - Radiotherapy

Poster Area/Exhibition Hall

PB-087  Hypofractionated boost to the tumor bed in early breast cancer: Skin toxicity analysis
G. Oses, T.D. Barreto, C. Cases, C. Castro, A. Lloret, J. Saéz, M. Mollà (Spain)

PB-088  Exposure of the oesophagus in breast cancer radiotherapy: a systematic review of oesophageal doses published 2013-2018
F. Duane, A. Kerr, M. Aznar, Z. Wang, C. Taylor (Ireland)
PB-089  Chronic toxicity after intraoperative electron radiotherapy as boost followed by whole breast irradiation
G. Oses, M. Mollà, I. Alonso, X. Caparros (Spain)

PB-091  Central review of radiation therapy planning among patients (pts) with breast-conserving surgery (BCS): results from a quality assurance process integrated into the INSEMA trial

PB-092  Early invasive ductal breast cancer: review after 5-year median follow-up of the first 681 patients treated by partial breast irradiation with intraoperative electron radiation therapy
C. Philippson, S. Simon, C. Vandekerkhove, I. Veys, D. Noterman, F. De Neubourg, M. Roman, J.M. Nogaret, D. Larsimont, A. Desmet (Belgium)

PB-093  The effect of a decision aid for breast cancer patients deciding on their radiation treatment
D. Raphael, N. Russell, T. Van der Weijden, L. Boersma (Netherlands)

PB-094  Resource to prepare patients for deep inspiration breath hold: The RESPIRE project
H. Probst, J. Barry, H. Clough, M. Lindley, M. Russel, R. Keeley, J. Ulman, J. Willis, M. Burton (United Kingdom)

PB-095  Results of locoregional radiotherapy or axillary dissection in breast cancer with pN0(i+) and pN1mi nodal disease
A. Altinok, F. Tokat, N. Bese, U. Ince, C. Uras (Turkey)

PB-096  Prospectively registered acute toxicity in breast cancer patients undergoing adjuvant intensity modulated proton therapy

Poster Session: Optimal Diagnosis

Poster Area/Exhibition Hall

PB-097  Magnetic resonance imaging: role in the response to neoadjuvant therapy of breast cancer
A. Surace, G. Pasquero, C. Marengo, G. Menato, A. Ponti, M. Bortolini, V. Marra, M.P. Mano, M.G. Baù (Italy)

PB-098  Deep learning enables fully automated mitotic density assessment in breast cancer histopathology
M. Balkenhol, MD, P. Bult, D. Tellez, W. Vreuls, P. Claesens, F. Ciompi, J. Van der Laak (Netherlands)

PB-099  Prone, stereotactic, vacuum-assisted breast biopsy
M. Dr. Cs. Jánvári, G. Forrai, E. Riedl (Hungary)

PB-100  Same day estrogen, progesterone and HER2neu receptor assessment in breast cancer diagnosis using Core Wash Cytology
R.C. Van Den Oudenalder, J. Bulte, L. Strobbe, W. Vreuls (Netherlands)

PB-101  The relative eosinophil count in breast cancer as an emerging prognostic biomarker
C.E. Onesti, C. Josse, B. Beaumecker, D. Boulet, J. Thiry, V. Bours, G. Jerusalem (Belgium)

PB-102  Diagnostic work-up in women suspect for breast cancer in the Netherlands
S. Sielsing, M. Voets, K. Groothuis, L. Veneklaas, S. Manohar, M. Brinkhuis, J. Veltman, L. De Munc, L.F. De Geus-Oei, M. Broeders (Netherlands)

PB-103  Is sentinel lymph node biopsy necessary in the setting of microinvasive DCIS?
K. Desai, R. Pham, J. Shin, K. Horn, A. Harbhajanka, L. Sieck (USA)
Comparison of Breast Cancer Subtype Classification using Xpert® Breast Cancer STRAT4 Assay and Immunohistochemistry in 100 patients with Primary Breast Cancer
S. Janeva, T. Parris, S. Nasic, S. De Lara, K. Larsson, R.A. Audisio, R. Olofsson Bagge, A. Kovács (Sweden)

Reconsidering the management of palpable DCIS: a single institution audit

Evaluation of FES (16α-[18F]-fluoro-17β-estradiol) PET for (re)staging of patients with clinical (locally) advanced or locoregional recurrent estrogen receptor positive breast cancer
R. Iqbal, C. Mo, M.C.F. Cysouw, A.W.J.M. Glaudemans, G.A.P. Hospers, C.P. Schroder, C.C.M. Venema, C.W. Menke-van der Houven van Oordt (Netherlands)

MRI accuracy in each immunophenotype to evaluate axillary tumour load after neoadjuvant treatment

MRI accuracy in each immunophenotype to evaluate axillary tumour load after neoadjuvant treatment

Digital breast tomosynthesis in the practice on the Clinic of Radiology - retrospective study
J. Slapodnikova, Doc.-CSc., V. Melus, K. Kasliкова, Z. Krajcovicova (Slovak Republic)

External validation of the Swedish SUS nomogram in 2939 breast cancer patients to predict disease-free axilla in primary breast cancer
L. Dihge, S. Majid, P.O. Bendahl, L. Huss, J. Manjer, L. Rydén (Sweden)

Development of a qPCR based ER signaling pathway activity test predictive for response to endocrine therapy in ER IHC positive breast cancer patients

Prognostic factors and patterns of recurrence of early mucinous breast cancers
A. Raman, E. Beh, R.Y.C. Tan, W.S. Ong, V. Tan, I. Jabeed, F.Y. Wong, Y.S. Yap (Singapore)

Enhanced axillary assessment using contrast enhanced ultrasound (CEUS) before neo-adjuvant systemic therapy (NACT) in breast cancer patients identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relevant
K. Cox, N. Dineen, J. Weeks, D. Allen, D. Akolekar, R. Chalmers, R. Burcombe, R. Jyothirmayi, C. Abson (United Kingdom)

More precise mitotic count and estrogen/progesteron (ER/PR) scoring system impact on grading in pre- and post-neoadjuvant primary breast cancer: morphological, clinical and radiological assessment.

Scalp cooling system to prevent alopecia: effectiveness, psychological effects and feasibility
A. Guglielmi, E. Durizzotto, S. Bradaschisa, B. Marzocchini, M. Malagoli, M. Ramella, F. Zanconati, M. Bortul, B. Scaggiante, F. Giudici, L. Dudine (Italy)

Patient-reported outcome measures used for reporting late effects in postmenopausal breast cancer survivors and compared to general symptoms in a danish female age matched population
A.W.M. Nielsen, M.H. Kristensen, B.V. Offersen, J. Alsner, R. Zachariae, H.M. Nielsen (Denmark)

Evaluation of the use of primary and hospital care in long-term breast cancer survivors: a longitudinal study based on real-world data

<table>
<thead>
<tr>
<th>Poster Session: Risk Factors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PB-118 Mobile health (mhealth) to improve quality of life in breast cancer survivors: study</strong></td>
<td>360</td>
</tr>
<tr>
<td><strong>protocol for randomized controlled trial</strong></td>
<td></td>
</tr>
<tr>
<td><strong>M. Kaur, B.S. Yadav, D. Dahiya, A. Akhilesh, S. Kaur, G. S. S. Ghai (India)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-119 Preoperative systemic treatment in breast cancer patients. Does the site of response</strong></td>
<td>361</td>
</tr>
<tr>
<td><strong>matter?</strong></td>
<td></td>
</tr>
<tr>
<td><strong>A. Esgueva, C. Siso, I. Miranda, C. Sobrido, M. Espinosa, R. Isabel (Spain)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-120 Use of oral complementary-alternative medicine (OCAM) and fatigue among early</strong></td>
<td>362</td>
</tr>
<tr>
<td><strong>breast cancer (BC) patients (pts)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>N. Diehal, J. Havas, A. Gbenou, E. Martin, C. Charles, S. Dauchy, B. Pistilli, C. Cadeau, P.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Arvey, S. Everhard, J. Lemonnier, C. Coutant, P. Cottu, A. Lesur, G. Menvielle, A. Dumas,</strong></td>
<td></td>
</tr>
<tr>
<td><strong>F. Andre, S. Michiels, I. Vaz-Luis, A. Di Meglio (France)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-121 What signals cancer survivorship when revealed during the job application process</strong></td>
<td>363</td>
</tr>
<tr>
<td><strong>to employers?</strong></td>
<td></td>
</tr>
<tr>
<td><strong>A. Sharipova, S. Baert (Belgium)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-122 Methylation of Glutathione-S-Transferase P1 Promoter in Egyptian females with</strong></td>
<td>364</td>
</tr>
<tr>
<td><strong>breast cancer</strong></td>
<td></td>
</tr>
<tr>
<td><strong>M. Eldeeb, T. Moghazy, H. Elattar, A. Farouk, R. Rashad (Egypt)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-123 Methylene Tetrahydrofolate Reductase gene (C677T) polymorphism and serum folate</strong></td>
<td>365</td>
</tr>
<tr>
<td><strong>level as risk factors of breast cancer among Egyptian females</strong></td>
<td></td>
</tr>
<tr>
<td><strong>M. Eldeeb, T. Moghazy, G. Khalil, H. Elsheredy (Egypt)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-125 The REMAR (Rhein-Main-Registry)-Study: Prospective evaluation of oncotype DX®</strong></td>
<td>367</td>
</tr>
<tr>
<td><strong>Assay in Addition to Ki-67 for adjuvant treatment decisions in early breast cancer</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Schulmeyer, B. Gabriel, D. Mosch, S. Buchen, E. Krapfl, U. Hurst, M. Vescia, H. Tesch, S.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Aulmann, C. Jackisch (Germany)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-126 Association between tumor metabolism assessed by 18F-FDG PET-CT and molecular</strong></td>
<td>368</td>
</tr>
<tr>
<td><strong>biological markers in luminal B type breast cancer</strong></td>
<td></td>
</tr>
<tr>
<td><strong>H.J. Lee, H.S. Kim, W.Y. Kim, S.U. Woo, J.B. Lee (South Korea)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-127 Change in trend in various clinic o-pathological factors and treatment profile of</strong></td>
<td>369</td>
</tr>
<tr>
<td><strong>breast cancer patients in developing countries: a tertiary cancer center experience</strong></td>
<td></td>
</tr>
<tr>
<td><strong>S. Sharma (India)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-128 Implication of atypical supraclavicular F18-fluorodeoxyglucose uptake in patients</strong></td>
<td>370</td>
</tr>
<tr>
<td><strong>with breast cancer: Relationship between brown adipose tissue and TILs, PD-L1</strong></td>
<td></td>
</tr>
<tr>
<td><strong>T. Fuji, E. Nishiki, M. Endo, S. Tokuda, Y. Nakazawa, S. Kurozumi, S. Obayashi, R. Yajima,</strong></td>
<td></td>
</tr>
<tr>
<td><strong>A. Katayama, T. Oyama (Japan)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-129 Relationship between FDG uptake and platelet/lymphocyte ratio in patients with</strong></td>
<td>371</td>
</tr>
<tr>
<td><strong>breast invasive ductal cancer</strong></td>
<td></td>
</tr>
<tr>
<td><strong>M. Endo, E. Nishiki, S. Tokuda, Y. Nakazawa, S. Kurozumi, S. Obayashi, R. Yajima, T. Fuji</strong></td>
<td></td>
</tr>
<tr>
<td><strong>(Japan)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-130 Role of immunohistochemical determination of Bcl-2 and p53 expression in</strong></td>
<td>372</td>
</tr>
<tr>
<td><strong>identifying hormone receptors positive/Her 2 negative (Luminal-like) high-risk breast</strong></td>
<td></td>
</tr>
<tr>
<td><strong>cancer patients</strong></td>
<td></td>
</tr>
<tr>
<td><strong>G. Dajti, G. Cisternino, M. Serra, A. Pellegrini, S. Zanotti, C. Ceccarelli, D. Santini,</strong></td>
<td></td>
</tr>
<tr>
<td><strong>M. Taffurelli (Italy)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PB-131 Evaluation of FISH of ER-positive breast cancer with low-HER2 expression could</strong></td>
<td>373</td>
</tr>
<tr>
<td><strong>improve their survival.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>T. Higuchi, F. Arisawa, Y. Hayashi, I. Manabe, K. Suekuni, A. Adachi, T. Saito (Japan)</strong></td>
<td></td>
</tr>
</tbody>
</table>
Does concomitant DCIS affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective

W.P. Lee, S.S. Shetty, C.M.J. Seah, P.T. Tan, S.M. Tan (Singapore)

Breast cancer patients undergoing delayed deep inferior epigastric perforator (DIEP) flap reconstruction differ from their matched controls by a higher socioeconomic status and better overall survival

H. Adam, A.C. Docherty Skogh, J. Frisell, J. De Boniface (Sweden)

Clinical prediction models for patients diagnosed with breast cancer: A systematic review

T. Hueting, M. Van Maaren, H. Koffijberg, S. Siesling (Netherlands)

Circulating tumour DNA as a prognostic biomarker in predicting breast cancer outcomes: systematic review and meta-analysis


Factors affecting locoregional recurrence rate of breast conserving surgery in patients with neoadjuvant chemotherapy


Evaluation of synthesized 2D mammography visibility with same pixel pitch as full-field digital mammography

Y. Furuya, Y. Goto, K. Tsugawa, Y. Kanemaki (Japan)

Patterns of treatment and outcome of ductal carcinoma in situ for population-based screened women

J. Luiten, E.J.T. Luiten, M.J.C. Van der Sangen, W. Vreuls, L.E.M. Duijnm, V.C.G. Tjan-Heijnen, A.C. Voogd (Netherlands)

Feasibility and comparison study of augmented breast self examination vs. conventional breast self examination rural Indian women for early detection- results of POC study

N. Vaddeboina, S. Attili, S. Peri, C. Sunkavalli, P. Dilip (India)

Breast Cancer Screening in undeveloped country. How precision medicine will help?

A. Fatima (Pakistan)

Current status for breast density notification in Japan


Patients’ experience with mammography and attitude towards targeted breast ultrasound as initial imaging technique for the evaluation of focal breast complaints

C. Siebers, L. Appelman, P. Appelman, S. Go, M. Van Oirsouw, M. Broeders, R. Mann (Netherlands)

Communication of biopsy results: a breast radiologist task?

V.A. Vitale, F. Meani, M. Manganiello, C. Catanese, F. Del Grande, S. Rizzo (Switzerland)

Breast cancer risk assessment combined with a polygenic risk score in the general population for personalized screening


Cost-effectiveness of different digital mammography screening strategies in the Netherlands

L. Kresting, V. Sankating, E. Heijnsdijk, N. Van Ravesteyn, H. De Koning (Netherlands)

Organisational characteristics of informed decision-making implementation in mammography screening programmes in 28 European countries

D. Ritchie, G. Van Hal, S. Van Den Broucke (Belgium)
Breast Incidentalomas. How often do they are? – A 5-year Greek hospital experience
A. Mitrousias, P. Karathanasis, V. Kalles, M. Matiatou, G. Georgiou, E. Zografiou, N. Michalopoulos, G. Zografos (Greece)

You Tube as a source of information for breast-examination for patients and healthcare professionals: content, quality and reliability
K. Rangarajan, T. Chouari, M. Uhercik, H. Osman, R. Daoud, L. Iain, I. Karat (United Kingdom)

**EBCC-12 Scientific programme**

**Friday 20 March 2020**

Society Session: European SocieTy for Radiotherapy & Oncology (ESTRO) - State of the Art in Radiation Oncology 2020

08:00 - 09:30 Goya

Chair: Dorota Gabrys (Poland)
Chair: Pedro C Lara (Spain)

08:00 **The best treatment in breast cancer radiotherapy 3D vs. IMRT**
Speaker: Icro Meattini (Italy)

08:20 **Is there a place for SBRT in multiple metastases breast cancer?**
Speaker: Dorota Gabrys (Poland)

08:40 **Are there breast cancer patients for which radiotherapy can be safely omitted after BCT?**
Speaker: Philip Poortmans (Belgium)

09:00 **Opportunities and challenges of combining radiotherapy immunotherapy in breast cancer patients**
Speaker: Pedro C Lara (Spain)

09:20 **Q & A**

Teaching Lecture: Nipple Sparing Mastectomy: Indications and Pitfalls

08:30 - 09:00 Picasso

08:30 **Nipple Sparing Mastectomy: Indications and Pitfalls**
Speaker: Oreste Gentilini (Italy)
Teaching Lecture: Big Data: Help or Hindrance?

08:30 - 09:00 Dali

08:30  Big Data: Help or Hindrance?
       Speaker: Fabrice André (France)

Teaching Lecture: Management of Low Risk DCIS

09:00 - 09:30 Picasso

08:30  Management of Low Risk DCIS
       Speaker: Jelle Wesseling (Netherlands)

Teaching Lecture: How to Manage Pain in Post-Surgical and Metastatic Settings

09:00 - 09:30 Dali

09:00  How to Manage Pain in Post-Surgical and Metastatic Settings
       Speaker: Nathan I. Cherny (Israel)

Clinical Science Symposium: Immuno-oncology in Breast Cancer

10:00 - 10:45 Picasso

Chair: G. Viale (Italy)

Chair: Tanja Spanic (Slovenia)

10:00  Pathology
       Speaker: Roberto Salgado (Belgium)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
<th>Speaker</th>
<th>Abstract Title</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td><strong>Systemic therapy</strong></td>
<td></td>
<td>Carmen Criscitiello (Italy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>Side effects</strong></td>
<td></td>
<td>A. Varga (France)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Proffered Paper Session: Are you breasts still at risk?</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>-</td>
<td>Eva Schumacher-Wulf (Germany)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Risk of subsequent in situ and invasive lesions after a primary diagnosis of ductal carcinoma in situ with follow-up time up to 28 years</td>
<td>Maartje Van Seijen (Netherlands)</td>
<td></td>
<td></td>
<td>14</td>
</tr>
<tr>
<td>10:55</td>
<td>Differences in breast cancer risk after a benign breast disease according to the screening type</td>
<td>Marta Roman (Spain)</td>
<td></td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>11:05</td>
<td>Contralateral breast cancer in patients with ductal carcinoma in situ and invasive breast cancer in the Netherlands</td>
<td>Daniele Giardiello (Netherlands)</td>
<td></td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>11:15</td>
<td>Discussant: Peter Dubsky (Switzerland)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Clinical Science Symposium: Early Breast Cancer and Germline Gene Panel Results: Help!</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>-</td>
<td>Gareth Evans (United Kingdom)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Imaging</td>
<td>Marjanka K. Schmidt (Netherlands)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>-</td>
<td>Rubina M. Trimboli (Italy)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>Gene panel testing for breast cancer: the geneticists viewpoint</td>
<td>Gareth Evans (United Kingdom)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. What is the added value of testing for additional breast cancer genes beyond BRCA1/2?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. What definition is there for an actionable breast cancer gene?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Are their specific categories of breast cancer (age, pathology, family history) that predicts higher rates of additional genes?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clinical Science Symposium: Advances in Imaging

10:00 - 11:30  Goya

Chair: Geraldine Gebhart (Belgium)
Chair: Francesco Sardanelli (Italy)

10:00  PET/CT imaging
Speaker: Geraldine Gebhart (Belgium)

10:15  Molecular imaging (novel tracers)
Speaker: Carolina Schröder (Netherlands)

10:30  Breast imaging
Speaker: Katja Pinker-Domenig (Austria)

Know the currently available and emerging advanced breast imaging modalities
Recognize the principle of digital breast tomosynthesis, contrast-enhanced mammography, multiparametric MRI and PET/MRI
Identify the individual potential and challenges of each technique

10:45  Determinants of mammographic density change
Oral Abstract SP: Shadi Azam (Sweden)
Debate: This House Believes That all Node Positive Patients Need Post Mastectomy Radiation

11:45 - 12:45  

Moderator: Emiel J. T. Rutgers (Netherlands)

11:45  Speaker in favour: Birgitte Offersen (Denmark)

12:00  Speaker against: Mike Dixon (United Kingdom)

1. Understand that many mastectomies are avoidable - best way to stop mastectomy and irradiation is to avoid mastectomy.
2. Appreciate that there is significant morbidity associated with post mastectomy radiotherapy particularly in patients undergoing breast reconstruction.
3. Be aware that many of the studies of post mastectomy radiotherapy were performed before the modern era of chemotherapy +/- antiHER2 agents and that local recurrence rates after mastectomy are reducing.

12:15  Seconder in favour: Philip Poortmans (Belgium)

12:25  Seconder against: Christoph Thomssen (Germany)

12:35  Voting/Conclusion

Best Practice Session: The Management of Metastatic Elderly Patient

11:45 - 12:45  

Chair: M. Aapro (Switzerland)

11:45  Assessment

Expert: Hans Wildiers (Belgium)

- explain how to assess older patients with cancer concerning their general health status (a process called geriatric assessment)
- explain why such an assessment is important

11:55  Unfit patient

Expert: Laura Biganzoli (Italy)

1. Provide a definition of the UNFIT patient
2. Identify the challenges related to the treatment of unfit patients
3. Report available data related to their treatment

12:05  
**Fit patient**  
Expert: Etienne Brain (France)

**Nurse (Panel member)**  
Expert: Eva Gustafsson (Sweden)

**Patient (Panel member)**  
Expert: Ellen Verschuur (Netherlands)

12:15  
**Panel discussion**

**EUROPA DONNA Session: ECIBC (European Commission Initiative on Breast Cancer) Implementation Plans**

11:45 - 12:45  
**Goya**

11:45  
**Introduction: ECIBC and patient advocacy**  
Co-Chair: Susan Knox (Italy)

11:52  
**Overview of ECIBC**  
Co-Chair: Annett Janusch Roi (Belgium)

12:00  
**European breast cancer guidelines**  
Speaker: Axel Grawlingholt (Belgium)

12:15  
**The European quality assurance scheme**  
Speaker: Robert E. Mansel (United Kingdom)

12:25  
**Implementation of ECIBC by breast cancer services: Practical aspects**  
Speaker: Luciana Neamtiu (Italy)

The European Commission Initiative on Breast Cancer (ECIBC) Quality Assurance (QA) Scheme defines a common set of quality and safety requirements for breast cancer services in Europe, as well as training requirements for professionals involved in breast cancer care. It focuses on aspects that are relevant to citizens and patients, and covers all the relevant care processes from screening until the end-of-life care. The QA Scheme adheres to evidence-based guidelines. This has been linked with achieving better health outcomes.

The QA Scheme aims to support quality breast cancer care across Europe and decrease inequalities in care. Implementation of the scheme is voluntary. The initiative has been developed in a flexible way, adaptable to national contexts.

Additional resources are available to support implementation of the ECIBC. These are all free to access from the ECIBC website and can be independently used to monitor and improve the quality of breast cancer care.

12:35  
**Discussion**
Closing Plenary Session: Keynote Lecture and Manifesto Session

13:00 - 14:30  Picasso

Chair: Nadia Harbeck (Germany)
Co-Chair: Tanja Spanic (Slovenia)
Chair: Javier Cortés (Spain)

13:00  Endocrine resistance and how it affects management in your daily practice
Keynote Speaker: Nick Turner (United Kingdom)

13:30  Manifesto session: Bridging the Gap Between Evidence Based Medicine and Reality – Why it is Needed - further info see separate session

Manifesto Session: Manifesto: Why don’t all European breast cancer patients get the most appropriate care?

13:30 - 14:30  Picasso

Medical Oncologist
Chair: Fátima Cardoso (Portugal)

Radiation Oncologist
Chair: Philip Poortmans (Belgium)

Surgeon
Panel: Fiona MacNeill (United Kingdom)

Pathologist
Panel: Frédérique Penault-Llorca (France)

Medical Oncologist
Panel: Alexandru Eniu (Romania)

Health Technology Assessor
Panel: François Maignment (United Kingdom)

Imaging
Panel: Francesco Sardanelli (Italy)

Patient Advocate
Panel: Elizabeth Bergsten-Nordstrom (Sweden)
President European Breast Cancer Council (EBCCouncil)
Panel: Emiel J. T. Rutgers (Netherlands)

Scientific writer
John Bean (Belgium)